Abstract: Methods for treating malignancies including multiple myeloma (MM), methods for expanding immune cells, methods for characterizing and enhancing anti-tumor functions of immune cells, and methods for characterizing immune cell responses to agonist immunotherapies including decoy-resistant IL-18 (DR-18) therapies.

Abstract: Methods for treating malignancies such as hematological malignancies, including myeloma, that are resistant to tissue transplant treatments and that can be characterized by an increased risk of relapse or graft-versus-host disease (GVHD). A method for treatment includes transplanting a tissue that includes T cells to a subject, enriching for a stem-like memory T cell phenotype in the T cells, and stimulating the T cells to enhance a graft-versus-tumor (GVT) response of the T cells. The enriching for the stem-like memory T cell phenotype can include depletion of exhausted alloreactive T cells with a post-transplant cyclophosphamide (PT-Cy) treatment and the stimulating the T cells can include an agonist immunotherapy, such as a decoy-resistant IL-18 (DR-18) treatment, to enhance the GVT response.

Abstract: Embodiments of the present disclosure are directed to methods and compositions for inhibiting cytomegalovirus (CMV) in a transplant recipient. In some embodiments, the methods are directed to inhibiting CMV reactivation in a transplant recipient with a CMV-seropositive serological status, the method comprising administering an effective amount of a compound to block IL-6 function. In some embodiments, the methods are directed to preventing CMV infection in a transplant recipient, wherein a transplant donor has a CMV-seropositive serological status, the method comprising administering an effective amount of a compound to block IL-6 function. In still other embodiments, a composition comprising a compound to block IL-6 function is administered to a transplant recipient with a CMV-seropositive serological status to prevent CMV reactivation.

Abstract: The present disclosure relates to methods of reducing inflammation in the gastro-intestinal (GI) tract, and more specifically to methods of reducing the risk of transplant recipients developing graft-versus-host disease by reducing inflammation in the gut.

Abstract: Wearable systems and associated methods for treatment of a neurocognitive impairment, disease or disorder in patients including a wearable visual field occluder; an attachment system configured for releasably attaching the wearable visual field occluder to th patient during treatment such that, when attached to the patient, the visual field occluder blocks visual feedback of an arm movement of the patient; and an eyewear having at least one lens comprising a prism, wherein the eyewear is configured to be worn by the patient separate and unsupported by the wearable visual field occluder.

Abstract: Provided are wearable systems arid methods for treatment of a neurocognitive impairment, disease or disorder in a patient in need thereof comprising a visual field occluder useful, for example, in prism adaptation therapy.

Abstract: Provided are wearable systems and methods for treatment of a neurocognitive impairment, disease or disorder in a patient in need thereof comprising a visual field occluder useful, for example, in prism adaptation therapy.

Abstract: Provided are wearable systems and methods for treatment of a neurocognitive impairment, disease or disorder in a patient in need thereof comprising a visual field occluder useful, for example, in prism adaptation therapy.

Abstract: The present invention relates to a preparation comprising at least one encapsulation material and at least one bioactive natural substance, which bioactive natural substance can be released from the preparation in a controlled manner, wherein the encapsulation material comprises at least one glyceride with a melting point of at least 35° C. and additionally at least one polymer with polyester units, which has a melting temperature of at least 30° C. and a viscosity in the range from 50 mPa*s to 250 Pa*s, measured by means of rotational viscometry at 110° C. The present invention further describes processes for producing the preparation of the invention, as well as preferred uses.

Abstract: The invention relates to a method for inducing immunological tolerance, in particular transplantation tolerance, by administering a G-CSF derivative or biologically active fragment, homolog, or variant thereof, in particular peg-G-CSF, to a donor cell or a transplantation donor. The invention also relates to expanding and stimulating selected donor cells by administering a G-CSF derivative, preferably peg-G-CSF. The donor cells are preferably granulocyte-monocyte precursor cells and IL-10 secreting T cells.

Abstract: The present invention relates to a newly identified hydrolase from thermophilic microorganisms having thermostable properties, and more specifically, to a novel thermostable hydrolase showing high activity at high temperatures.

Abstract: The invention provides encapsulated, microparticulate active ingredient formulations for the controlled release of active ingredients on skin and skin appendages consisting of encapsulation material as casing and at least one enclosed biologically active ingredient as core, which is characterized in that enzymatically degradable organic hyperbranched polymers containing ester groups are used as encapsulation material.

Abstract: The invention relates to a method, composition and use thereof for inducing immunological tolerance, in particular transplantation tolerance in a recipient and self-tolerance in a patient. Tolerance is preferably induced by administering a G-CSF derivative, or biologically active fragment, homolog or variant thereof, in particular peg-G-CSF, to a transplantation donor. Transplantation tolerance may reduce or prevent graft versus host disease or graft rejection and self-tolerance may prevent, treat or improve a condition in relation to an autoimmune disorder. The invention also relates to expanding and stimulating selected donor cells by administering a G-CSF derivative, preferably peg-G-CSF. The donor cells are preferably granulocyte-monocyte precursors cells and IL-10 secreting T cells.

Abstract: The invention is directed to the use of cpn10 in transplantation and particularly to treatment and/or prevention of graft versus host disease. The invention provides a method of administration of cpn10 to a donor and/or recipient animal or cells, tissues or organs derived from the donor, although in a particularly advantageous form treatment of both the donor and recipient animal. The method may further include the administration to the donor and/or recipient animal at least one other immunosuppressive agent to prevent or alleviate graft versus host disease.

Abstract: The present invention relates to processes for the production of acyl compounds using an esterase having thermostable properties, and to products of such processes.

Abstract: The present invention relates generally to a method of modulating the immunoactivity of a population of immune cells and, more particularly to a method of down-regulating the immunoactivity of an immunocompetent graft. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate graft immunoactivity such as, but not limited to, the prophylaxis treatment of graft versus host disease in allogeneic stem cell graft recipients.

Abstract: The present invention relates to a newly identified hydrolase from thermophilic microorganisms having thermostable properties, and more specifically, to a novel thermostable hydrolase showing high activity at high temperatures.

Abstract: The present invention relates to an enzymatic process for the preparation of hydroxy fatty acid esters which are solid at room temperature and have improved melting behavior. Specifically, the enzymatic process includes reacting di- or polyols having at least two primary and optionally secondary or tertiary, hydroxyl groups, and hydroxy fatty acids and/or hydroxy fatty acid alkyl esters, and optionally, removing water of reaction or alcohol of reaction which forms.

Abstract: The invention relates to compositions for controlling microoganisms, comprising primary and secondary esters of polyglycerol in an effective ratio of from 8:1 to 25:1.

Abstract: The invention relates to compositions for controlling microorganisms, with an effective content of enzymatically prepared mixtures of fatty acid monoesters and fatty acid diesters of polyglycerol.